429 related articles for article (PubMed ID: 21909397)
21. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
Carnevalli LS; Ghadially H; Barry ST
Front Immunol; 2021; 12():633685. PubMed ID: 33953710
[TBL] [Abstract][Full Text] [Related]
22. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor.
Carson WE; Giri JG; Lindemann MJ; Linett ML; Ahdieh M; Paxton R; Anderson D; Eisenmann J; Grabstein K; Caligiuri MA
J Exp Med; 1994 Oct; 180(4):1395-403. PubMed ID: 7523571
[TBL] [Abstract][Full Text] [Related]
23. Short-course IL-15 given as a continuous infusion led to a massive expansion of effective NK cells: implications for combination therapy with antitumor antibodies.
Dubois SP; Miljkovic MD; Fleisher TA; Pittaluga S; Hsu-Albert J; Bryant BR; Petrus MN; Perera LP; Müller JR; Shih JH; Waldmann TA; Conlon KC
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33883258
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review).
Hoskin DW; Mader JS; Furlong SJ; Conrad DM; Blay J
Int J Oncol; 2008 Mar; 32(3):527-35. PubMed ID: 18292929
[TBL] [Abstract][Full Text] [Related]
25. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
[TBL] [Abstract][Full Text] [Related]
26. A role for transforming growth factor-beta 1 in regulating natural killer cell and T lymphocyte proliferative responses during acute infection with lymphocytic choriomeningitis virus.
Su HC; Leite-Morris KA; Braun L; Biron CA
J Immunol; 1991 Oct; 147(8):2717-27. PubMed ID: 1918986
[TBL] [Abstract][Full Text] [Related]
27. Cancer immunotherapy via targeted TGF-β signalling blockade in T
Li S; Liu M; Do MH; Chou C; Stamatiades EG; Nixon BG; Shi W; Zhang X; Li P; Gao S; Capistrano KJ; Xu H; Cheung NV; Li MO
Nature; 2020 Nov; 587(7832):121-125. PubMed ID: 33087933
[TBL] [Abstract][Full Text] [Related]
28. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
[TBL] [Abstract][Full Text] [Related]
29. Nano-chemical priming strategy to enhance TGF-β resistance and anti-tumor activity of natural killer cells.
Choi SH; Cho HB; Choi JH; Kim HJ; Jang HJ; Cho S; Maeng E; Park H; Ryu KS; Park KH; Park KS
J Control Release; 2024 Mar; 367():768-778. PubMed ID: 38341178
[TBL] [Abstract][Full Text] [Related]
30. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
31. Tailoring Natural Killer cell immunotherapy to the tumour microenvironment.
Barrow AD; Colonna M
Semin Immunol; 2017 Jun; 31():30-36. PubMed ID: 28935344
[TBL] [Abstract][Full Text] [Related]
32. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
33. M2-polarized and tumor-associated macrophages alter NK cell phenotype and function in a contact-dependent manner.
Krneta T; Gillgrass A; Poznanski S; Chew M; Lee AJ; Kolb M; Ashkar AA
J Leukoc Biol; 2017 Jan; 101(1):285-295. PubMed ID: 27493241
[TBL] [Abstract][Full Text] [Related]
34. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.
Trotta R; Dal Col J; Yu J; Ciarlariello D; Thomas B; Zhang X; Allard J; Wei M; Mao H; Byrd JC; Perrotti D; Caligiuri MA
J Immunol; 2008 Sep; 181(6):3784-92. PubMed ID: 18768831
[TBL] [Abstract][Full Text] [Related]
35. The cancer-natural killer cell immunity cycle.
Huntington ND; Cursons J; Rautela J
Nat Rev Cancer; 2020 Aug; 20(8):437-454. PubMed ID: 32581320
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction.
Ortaldo JR; Mason AT; O'Shea JJ; Smyth MJ; Falk LA; Kennedy IC; Longo DL; Ruscetti FW
J Immunol; 1991 Jun; 146(11):3791-8. PubMed ID: 1851793
[TBL] [Abstract][Full Text] [Related]
37. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
38. High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment.
Gonzalez VD; Huang YW; Delgado-Gonzalez A; Chen SY; Donoso K; Sachs K; Gentles AJ; Allard GM; Kolahi KS; Howitt BE; Porpiglia E; Fantl WJ
Cell Rep; 2021 Aug; 36(9):109632. PubMed ID: 34469729
[TBL] [Abstract][Full Text] [Related]
39. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
Zhang S; Zhao J; Bai X; Handley M; Shan F
Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
[TBL] [Abstract][Full Text] [Related]
40. An acidic microenvironment impairs the generation of non-major histocompatibility complex-restricted killer cells.
Müller B; Fischer B; Kreutz W
Immunology; 2000 Mar; 99(3):375-84. PubMed ID: 10712667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
